FIA
COGT icon

FNY Investment Advisers’s Cogent Biosciences COGT Stock Holding History

FNY Investment Advisers’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-14
Closed – – 1018
2025
Q3 		$0 Buy
+14
New +$166 ﹤0.01% 1270
2018
Q4 		– Sell
-3
Closed – – 735
2018
Q3 		$0 Buy
+3
New +$169 ﹤0.01% 960

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

FNY Investment Advisers's COGT Position: Q4 2025 in Review

FNY Investment Advisers sold out of Cogent Biosciences (COGT) in Q4 2025, closing a stake of 14 shares.

FNY Investment Advisers first reported a position in COGT in Q3 2018 and held it in 2 quarters. The position peaked at $0 in Q3 2025. 267 funds tracked by Wall St. Rank hold COGT as of Q4 2025.

  • FNY Investment Advisers reported no remaining Cogent Biosciences position as of Q4 2025 after selling out during the quarter.
  • FNY Investment Advisers sold 14 Cogent Biosciences shares in Q4 2025.
  • FNY Investment Advisers first reported a position in Cogent Biosciences in Q3 2018 and held it in 2 quarters.
  • FNY Investment Advisers's Cogent Biosciences position peaked at $0 in Q3 2025.
  • 267 funds tracked by Wall St. Rank held Cogent Biosciences as of Q4 2025.

Based on FNY Investment Advisers's 13F filing for Q4 2025, filed 16 Jan 2026.